Drugs that inhibit fatty acid oxidation or interfere with lipid signaling pathways, such as inhibitors of ALOX5AP or FABP5, could serve as potential therapies for GBM by impairing the metabolic fitness of TAMs and reactivating anti-tumor immunity (37). Here, FABP5 is linked to glioblastoma.